Skip to content

NanOss Bioactive With Autograft and Bone Marrow Aspirate in the Posterolateral Spine

A Prospective, Nonrandomized Study to Assess Lumbar Fusion With Instrumented Posterolateral Gutter Fusions Using NanOss Bioactive

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02005341
Enrollment
0
Registered
2013-12-09
Start date
2011-10-31
Completion date
2014-09-30
Last updated
2017-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Spinal Stenosis Secondary to Other Disease

Keywords

Lumbar, fusion

Brief summary

The purpose of this study is to assess lumbar fusion using nanOss Bioactive bone void filler

Interventions

DEVICEnanOSS
DEVICEAutograft

Sponsors

Pioneer Surgical Technology, Inc.
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Is at least 21 years of age and skeletally mature. 2. Must have cervical disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies) at one level in the cervical spine between C3 to T1. 3. Must have completed a minimum of six weeks of unsuccessful conservative, non-operative care or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment. 4. Has pre-operative objective evidence of primary diagnosis confirmed by appropriate imaging studies (Anteroposterior/Lateral/Flexion/Extension X-rays & a recent MRI). 5. Is willing and able to comply with all clinical investigation visits and procedures including screening treatment procedures, post-operative management, the follow-up schedule and completion of forms or questionnaires. 6. Is able to understand and sign the patient information sheet/informed consent form.

Exclusion criteria

1. Requires fusion at more than one level. 2. Has had prior fusion at the level to be treated. 3. Has a metabolic or systemic bone disorder. 4. Has a disease that significantly inhibits bone healing (i.e., severe osteoporosis, osteomalacia, Paget's disease). 5. Has a systemic or local infection (active or latent). 6. Has acute or chronic infections in the surgical area (i.e., soft tissue infections; inflammatory, bacterial bone disorders, osteomyelitis). 7. Chronic use of steroids, other than episodic use or inhaled corticosteroids. 8. Has any significant general illness (i.e., HIV, active metastatic cancer of any type, uncontrolled diabetes Type I, dialysis dependent renal failure, symptomatic liver disease). 9. Has a mental or physical condition that would limit the ability to comply with study requirements or would preclude accurate evaluation. 10. Is immunocompromised or being treated with immunosuppressive agents (including chemotherapy or radiation treatment). 11. Has documented allergies to hydroxyapatite or porcine collagen, PEEK, titanium, titanium alloy or tantalum. 12. Is currently pregnant, or interested in becoming pregnant during the clinical investigation follow-up. 13. Is a smoker. 14. Is non-English speaking. 15. Requires the use of a bone-growth stimulator. 16. Is a prisoner. 17. Is currently involved in another drug or device clinical investigation that may confound the clinical trial investigation

Design outcomes

Primary

MeasureTime frame
Fusion at 12 months postoperatively.12 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026